United Therapeutics (UTHR) Other Non-Current Assets (2009 - 2026)

United Therapeutics has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $233.2 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $233.2 million, up 4.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $233.2 million (up 4.86% YoY), and the FY2025 annual result was $196.9 million, down 11.35% from the prior year.
• Other Non-Current Assets came in at $233.2 million for Q1 2026 at United Therapeutics, up from $196.9 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $262.6 million in Q3 2025 to a low of $105.8 million in Q2 2022.
• The 5-year median for Other Non-Current Assets is $167.9 million (2024), against an average of $170.2 million.
• Across the five-year window, Other Non-Current Assets plunged 40.23% in 2022 and surged 46.31% in 2024, its largest moves.
• United Therapeutics' Other Non-Current Assets stood at $114.3 million in 2022, then soared by 32.81% to $151.8 million in 2023, then soared by 46.31% to $222.1 million in 2024, then fell by 11.35% to $196.9 million in 2025, then increased by 18.44% to $233.2 million in 2026.
• The last three Other Non-Current Assets figures came in at $233.2 million (Q1 2026), $196.9 million (Q4 2025), and $262.6 million (Q3 2025), per Business Quant data.